FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis

We  know that, Rivaroxaban (structure below BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceuticals. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible....

Now FDA Approves Xarelto (rivaroxaban) to Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery....

More....

Sulforaphane-rich foods safe and effective for preventing cancer

In continuation of my update on the benefits of broccoli and  sulforaphane............

Sulforaphane-rich foods safe and effective for preventing cancer

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

Pharmasset receives U.S. patent titled 'Nucleoside Phosphoramidate Prodrugs'

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

We know that Bardoxolone methyl (see the structure, also known as “RTA 402” and “CDDO-methyl ester) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant inflammation modulator (AIM) class. It is the most potent known inducer of the Nrf2 pathway to enter clinical development and works to suppress both oxidative stress and inflammation.......

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

Potential new approach for treating obesity, type 2 diabetes

Potential new approach for treating obesity, type 2 diabetes

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

Antimicrobial copper surfaces reduce risk of acquiring hospital infection

New and effective diabetes drug seeking approval

We know that, Dapagliflozin is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1 and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucosereabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
New and effective diabetes drug seeking approval

New clot busting drug approved in UK

In continuation of my update on Ticagrelar.........

New clot busting drug approved in UK

Heterocycles glossary - organic-reaction.com

Heterocycles glossary - organic-reaction.com

Strawberries improve antioxidant capacity of blood

In continuation strawberries...
Strawberries improve antioxidant capacity of blood

U.S. FDA approves generic Levaquin for treatment of bacterial infections

U.S. FDA approves generic Levaquin for treatment of bacterial infections

FDA approves Watson's Nabumetone Tablets for treatment of osteoarthritis, RA

FDA approves Watson's Nabumetone Tablets for treatment of osteoarthritis, RA

Niclosamide drug effective against colon cancer metastasis

Niclosamide drug effective against colon cancer metastasis

Liraglutide as Additional Treatment in Type 1 Diabetes

In continuation of my update on Liraglutide...

 Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide (below structure) , an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control of their blood glucose levels.

More....

New drug more effective than standard treatment to prevent heart-attack deaths

In continuation of my update on ticagrelor .....

Robert Storey, Professor of Cardiology at the University of Sheffield's Department of Cardiovascular Science, presented findings today that confirm one in five deaths in the year following a heart attack could be prevented if a new drug, ticagrelor (see structure), was used instead of the standard treatment, clopidogrel...

More...